Eli Lilly: CMS decision on amyloid imaging is "contrary to expert opinion"

Eli Lilly and Co. expressed disappointment at the CMS' decision that stopped short of fully endorsing Amyvid, a PET beta-amyloid imaging drug used to assess Alzheimer's disease. The company said limiting access to Amyvid is "contrary to expert opinion" and violates the National Alzheimer's Project Act, which aims to develop new ways to diagnose and treat patients with the disease. "We will be evaluating all available options to ensure patients and physicians can gain access to this innovative diagnostic tool as soon as possible," a company statement said.

View Full Article in:

Indianapolis Star (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ